Cost-effectiveness analysis of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency in China

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-5)

Tables (1-2)

Sum=113

Publishing Process of This Article

Item

Count

Browse

Download

Sum=3

Aug 15, 2025 (publication date) through Aug 17, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Aug 15, 2025; 17(8): 109544
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.109544

Table 2 Results of the cost-effectiveness analyses

	Scenario 1 (unresectable pancreatic cancer)		Scenario 2 (pancreatic cancer post-surgery)		Scenario 3 (chronic pancreatitis after endoscopic treatment)
	PERT	No PERT	PERT	No PERT	PERT	No PERT
LYs	1.33	0.94	4.41	3.12	9.79	8.76
QALYs	0.94	0.49	3.22	1.64	7.65	4.72
Costs (dollar)	4960	645	15677	1743	17846	2653
ICER (LY/dollar)	10996		10763		14829
ICER (QALY/dollar)	9533		8813		5178

LY: Life year; QALY: Quality adjusted life year; ICER: Incremental cost-effectiveness ratio; PERT: Pancreatic enzyme replacement therapy.

Citation: Kim H, Byrnes J, Jiang KR, Liao Z, Jones A, Kim K, Fragkogianni D, Roberts KJ. Cost-effectiveness analysis of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency in China. World J Gastrointest Oncol 2025; 17(8): 109544
URL: https://www.wjgnet.com/1948-5204/full/v17/i8/109544.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i8.109544